戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 pediatric MAS varies based on the underlying rheumatic disease.
2 e in both adults and children diagnosed with rheumatic disease.
3  estimated the sex-specific lifetime risk of rheumatic disease.
4  MTX initiation among diabetes patients with rheumatic disease.
5 obin (HbA(1c) ) in diabetes patients without rheumatic disease.
6 rtunities to better understand the causes of rheumatic disease.
7  increasingly recognized in association with rheumatic disease.
8 recent advances in the field of diabetes and rheumatic disease.
9    Sjogren's syndrome is a common autoimmune rheumatic disease.
10 ity of life in children and adolescents with rheumatic disease.
11  adults secondary to infection, lymphoma, or rheumatic disease.
12 series was efficacious in an animal model of rheumatic disease.
13 s for use in pediatric patients with chronic rheumatic disease.
14  more activity limitations in the setting of rheumatic disease.
15 tion strategies among people with documented rheumatic disease.
16 al adjustment to and coping with a pediatric rheumatic disease.
17  standard and novel agents used in pediatric rheumatic disease.
18 ar disease, and malignancy) in patients with rheumatic disease.
19 in the absence of any objective indicator of rheumatic disease.
20 particularly as they relate to patients with rheumatic disease.
21  specific genetic factors to the spectrum of rheumatic disease.
22 rtant role in the risk of developing chronic rheumatic disease.
23 ician Scale is appropriate for patients with rheumatic disease.
24 nce of both inflammatory and noninflammatory rheumatic disease.
25 can result in the development of features of rheumatic disease.
26 hat has widely been used in the treatment of rheumatic disease.
27 ed with adverse birth outcomes in women with rheumatic disease.
28 e adverse metabolic features associated with rheumatic disease.
29 se phenotype in a mouse model of RRV-induced rheumatic disease.
30 therapeutic strategies for many inflammatory rheumatic diseases.
31 elopment of inflammatory diseases, including rheumatic diseases.
32 l syndromes that closely mimic other primary rheumatic diseases.
33 nized for noninfectious association with the rheumatic diseases.
34 ty for SLE and 87% specificity against other rheumatic diseases.
35  be difficult to distinguish from idiopathic rheumatic diseases.
36 , including systemic lupus erythematosus and rheumatic diseases.
37 gnify new associations between drugs and the rheumatic diseases.
38 ions of personalized, targeted therapies for rheumatic diseases.
39 esses and challenges and with an emphasis on rheumatic diseases.
40 ning an effective treatment strategy for the rheumatic diseases.
41  limit the safety of colchicine for treating rheumatic diseases.
42 d localized and generalized bone loss in the rheumatic diseases.
43 ide an effective nonsurgical intervention in rheumatic diseases.
44 emity joint alignment, structure and pain in rheumatic diseases.
45 f foot orthotics and footwear in adults with rheumatic diseases.
46  and interventions that lessen the impact of rheumatic diseases.
47 medical conditions, including the autoimmune rheumatic diseases.
48  of the frequency of PML among patients with rheumatic diseases.
49 for the pathogenesis of chronic inflammatory rheumatic diseases.
50 doption of telemedicine in the management of rheumatic diseases.
51 ML occurs more commonly in SLE than in other rheumatic diseases.
52 with juvenile idiopathic arthritis and other rheumatic diseases.
53 ns of anti-PAD-4 autoantibodies in different rheumatic diseases.
54 , may influence the occurrence of autoimmune rheumatic diseases.
55  its role in the pathogenesis of more common rheumatic diseases.
56 majority of inflammatory and noninflammatory rheumatic diseases.
57 se of their recent success in treating other rheumatic diseases.
58 at may be also useful in patients with other rheumatic diseases.
59  a potentially fatal complication of chronic rheumatic diseases.
60 lines on the use of ultrasound modalities in rheumatic diseases.
61 or for work disability in a diverse array of rheumatic diseases.
62 A helicase A (RHA) in patients with systemic rheumatic diseases.
63 ents have found expanded indication in other rheumatic diseases.
64 est in pharmacoeconomic evaluations in other rheumatic diseases.
65 dated and expanded upon the costs of various rheumatic diseases.
66 rs as they pertain to rehabilitation and the rheumatic diseases.
67 literature concerning work disability in the rheumatic diseases.
68 be increased in association with many of the rheumatic diseases.
69 redispositions, and therapies similar to the rheumatic diseases.
70 a on pregnancy outcomes in women with common rheumatic diseases.
71  psychological well-being among persons with rheumatic diseases.
72 was selected from the National Data Bank for Rheumatic Diseases.
73 ain and pain-related sequelae across several rheumatic diseases.
74  peptides play an important role in juvenile rheumatic diseases.
75 tial lung disease frequently complicates the rheumatic diseases.
76 the validity of the QWB-SA for patients with rheumatic diseases.
77 have been validated in patients with diverse rheumatic diseases.
78 s and novel biologic agents in children with rheumatic diseases.
79 udies, and may prove useful in other complex rheumatic diseases.
80 therapies used in the treatment of pediatric rheumatic diseases.
81  transplant agents used to treat the various rheumatic diseases.
82 represents a therapeutic option for systemic rheumatic diseases.
83 ct costs, as well as the personal impact, of rheumatic diseases.
84  known targets of autoantibodies in systemic rheumatic diseases.
85 les from patients with systemic immune-based rheumatic diseases.
86 to treat patients with a variety of systemic rheumatic diseases.
87 ave an increased risk of developing systemic rheumatic diseases.
88 chosocial issues for children with pediatric rheumatic diseases.
89  and chronic inflammatory conditions such as rheumatic diseases.
90 e approach to the diagnosis and treatment of rheumatic diseases.
91 of autoimmune diseases, including autoimmune rheumatic diseases.
92 ich are central to the pathogenesis of these rheumatic diseases.
93 g MIF-related genetic susceptibility to many rheumatic diseases.
94 t insights into the complicated aetiology of rheumatic diseases.
95 for the treatment of a variety of autoimmune rheumatic diseases.
96 r pathways that underpin the pathogenesis of rheumatic diseases.
97 hway might in fact have clinical benefits in rheumatic diseases.
98 inant Fc fusion protein widely used to treat rheumatic diseases.
99 ows one of the highest mortality rates among rheumatic diseases.
100 lidates uPA as a novel therapeutic target in rheumatic diseases.
101 udied areas include the muscles, tendons and rheumatic diseases.
102 , chronic obstructive pulmonary disease, and rheumatic diseases.
103  pregnancy and the future risk of autoimmune rheumatic diseases.
104 are critical to the pathogenesis of systemic rheumatic diseases.
105 been tested as therapeutics for inflammatory rheumatic diseases.
106  pregnancy-related research in patients with rheumatic diseases.
107 e of this biologic is now expanding to other rheumatic diseases.
108 ntal role in the diagnosis and monitoring of rheumatic diseases.
109 ertinent to the pathogenesis or treatment of rheumatic diseases.
110 h are defective, but correctable, in several rheumatic diseases.
111                                    Among the rheumatic diseases, 43 cases of PML (0.44%) were associa
112 5.5% vs. 0.1%), pancreatic (1.7% vs. 0%) and rheumatic diseases (7.2% vs. 1.2%; all P < 0.01).
113 with neonatal lupus syndromes do not develop rheumatic diseases, although follow-up is limited to lat
114 btained from our population-based studies of rheumatic diseases among residents of Olmsted County, Mi
115 lales abundance are implicated in arthritis, rheumatic disease and diabetes.
116 acity and physical activity in children with rheumatic disease and examines the role of exercise in m
117     However, patients with active underlying rheumatic disease and secondary infection who are being
118 iscussed, along with their putative roles in rheumatic disease and therapeutic options for targeting
119 t drugs used in other specialties may induce rheumatic disease and vigilance on making a diagnosis is
120  with aPL detected incidentally, 4 had other rheumatic diseases and 2 had other conditions.
121 ifferences in the occurrence and outcomes of rheumatic diseases and differences in treatment by ethni
122 ecificity in relation to patients with other rheumatic diseases and healthy controls was >90%.
123 SLE patients compared to patients with other rheumatic diseases and healthy subjects.
124 ic abnormality distinguishes SJIA from other rheumatic diseases and is caused by both genetic and acq
125                   Patients with inflammatory rheumatic diseases and periodontitis share common pathog
126 m remains a promising therapeutic target for rheumatic diseases and requires further study.
127 th content that was relevant to rheumatology/rheumatic diseases and that primarily focused on ethics.
128 on DNA methylation alterations in autoimmune rheumatic diseases and the advantages and disadvantages
129 ulated molecular mechanisms in patients with rheumatic diseases and the discovery of new therapeutic
130 marizes the effects pregnancy has on various rheumatic diseases and the effects these diseases have o
131  rheumatologists in caring for children with rheumatic diseases and the quality of the care that they
132                Children and adolescents with rheumatic diseases and their families face a multitude o
133 isks of malignancy associated with pediatric rheumatic diseases and their treatments are needed.
134 s have been developed and validated for many rheumatic diseases and used in clinical trials.
135 rised 12 patients with IBD, 17 patients with rheumatic disease, and 19 healthy individuals (controls)
136 logic lesion, the activity of the underlying rheumatic disease, and associated pulmonary hypertension
137 described as an autoantigen in patients with rheumatic disease, and Ro60 orthologs have been identifi
138 d (210 SLE patients, 178 patients with other rheumatic diseases, and 205 healthy subjects).
139           Job loss is a major consequence of rheumatic diseases, and clinicians may refer patients to
140 nts with established RA, patients with other rheumatic diseases, and healthy adults were assayed for
141 y was confined to hospitalized patients with rheumatic diseases, and it was also limited by the lack
142  are key pathogenic derangements in systemic rheumatic diseases, and these insights are leading to ch
143 ptive immune system like multiple sclerosis, rheumatic diseases, and type 1 diabetes.
144 ch exhibit differential association with the rheumatic disease ankylosing spondylitis (AS).
145 e use of immunomodulatory drugs, many of the rheumatic diseases appear to pose an increased risk for
146 ic bacteriuria (AB) in women with autoimmune rheumatic disease (ARD) are scarce.
147  Features that can have similarities to many rheumatic diseases are being increasingly reported.
148               Autoantibodies in the systemic rheumatic diseases are clinically useful biomarkers of t
149 ibroblasts in systemic sclerosis and related rheumatic diseases are discussed.
150                                   Autoimmune rheumatic diseases are genetically complex entities that
151                               As most of the rheumatic diseases are multisystem, it is worthwhile exa
152  This morbidity is undetermined in pediatric rheumatic disease as osteoporosis has not been well-defi
153 d between healthy children and children with rheumatic diseases as a group.
154 er its role in multifaceted diseases such as rheumatic diseases, as well as other autoimmune and infl
155          Scleroderma is a chronic autoimmune rheumatic disease associated with widespread tissue fibr
156 pneumonia accounts for a large proportion of rheumatic disease-associated interstitial lung diseases.
157        Macrophage activation syndrome is the rheumatic disease-associated member of a group of hyperi
158 le, other interventions are needed to reduce rheumatic disease-associated work disability.
159 the principles behind RNA sequestration by a rheumatic disease autoantigen, whereby the UUU(OH) 3' en
160          Ultrasound cannot identify specific rheumatic diseases, but it does allow for an evaluation
161 genitor/stem cells (MPCs) and their roles in rheumatic diseases, but little is known about the phenot
162 portant mediator of cartilage destruction in rheumatic diseases, but our understanding of the upstrea
163 tional biomarkers and therapeutic targets in rheumatic diseases, but the full potential of their appl
164 ologists document and improve the quality of rheumatic disease care.
165 siological mechanisms of musculoskeletal and rheumatic disease caused by SINV are inadequately unders
166 c lupus erythematosus (SLE), an inflammatory rheumatic disease characterized by autoantibody producti
167  were identified from patients attending the Rheumatic Diseases Clinic, Hospital de Santo Espirito, i
168 f 113 individuals (73% women) with diagnosed rheumatic disease completed a mailed questionnaire.
169 ystem dysfunction is common in children with rheumatic diseases complicated by MAS, and more organ sy
170 table proportion of individuals with chronic rheumatic diseases continue to be treated with these dru
171  specific genetic mechanisms involved in the rheumatic diseases continues to present considerable cha
172  48 SLE patients, 48 normal controls, and 22 rheumatic disease controls, and total RNA was extracted
173             Studies of children with chronic rheumatic disease demonstrate decreased bone mineral den
174 fficacy, and the safety of plasmapheresis in rheumatic diseases demonstrates that the answer depends
175 and safety of intravenous immunoglobulins in rheumatic diseases demonstrates that the answer depends
176 limitations in children and adolescents with rheumatic disease despite advances in the pharmacologica
177 ealth indicator that shows differences among rheumatic disease diagnoses.
178 ured medical record abstraction, we examined rheumatic disease diagnosis, cumulative steroid use, dur
179  men will develop an inflammatory autoimmune rheumatic disease during their lifetime.
180               The management of inflammatory rheumatic diseases during pregnancy and breastfeeding ha
181 ta concerning vaccination among persons with rheumatic diseases, focusing on the effects of immune-mo
182 ts promise to shape the care of RA and other rheumatic diseases for many years to come.
183                                Children with rheumatic diseases frequently require therapy with disea
184 ble Chikungunya-related chronic inflammatory rheumatic diseases (&gt;3 month symptom duration from the i
185  of Chikungunya-related chronic inflammatory rheumatic diseases had not been reported so far.
186     Although the management of patients with rheumatic diseases has evolved substantially over the pa
187  underlying the pathogenenesis of autoimmune rheumatic diseases has led to targeted biological treatm
188 S: New genetic associations in patients with rheumatic disease have been reported for disease modifyi
189                        Children with chronic rheumatic disease have decreased bone mass.
190                             Several juvenile rheumatic diseases have been linked to certain immunomod
191                                              Rheumatic diseases have complex aetiologies that are not
192                     The options for treating rheumatic diseases have improved, but many patients are
193  intracellular targets of glucocorticoids in rheumatic diseases have not been fully identified.
194 tological malignancies, Crohn's disease, and rheumatic diseases--have been associated with PML.
195                     Both atherosclerosis and rheumatic diseases, however, have a complicated cause, a
196 he highest case-specific mortality among the rheumatic diseases; however, advances in understanding o
197 ng of the immunopathology of childhood-onset rheumatic diseases; however, considerable impediments mu
198 sing results in preclinical animal models of rheumatic diseases, human clinical trials have, in gener
199 literature related to the risk of autoimmune rheumatic disease in association with pregnancy history.
200                      Although mortality from rheumatic disease in children is rare, the most severe d
201 squito-borne Alphavirus, causes debilitating rheumatic disease in humans that can last for weeks to m
202                             Gout is a common rheumatic disease in humans which is characterized by el
203 ging typical for the most commonly diagnosed rheumatic diseases in children, such as juvenile idiopat
204   Spondyloarthropathies belong to a group of rheumatic diseases, in which inflammatory changes affect
205 dal anti-inflammatory drugs in patients with rheumatic diseases, including children.
206 c lesions cause interstitial lung disease in rheumatic diseases, including nonspecific interstitial p
207                                     Finally, rheumatic diseases, including rheumatoid arthritis and s
208 RA, as well as other inflammatory autoimmune rheumatic diseases, including systemic lupus erythematos
209                           The diagnosis of a rheumatic disease is no longer an absolute contraindicat
210 of interstitial lung disease associated with rheumatic disease is similar to that associated with the
211                 Current therapy for juvenile rheumatic diseases is based on general immune suppressio
212 nce of cultural aspects of rehabilitation in rheumatic diseases is being increasingly recognized and
213                    Differential diagnosis of rheumatic diseases is performed on the basis of localiza
214 aphies that met inclusion criteria, selected rheumatic disease journals, and abstracts from scientifi
215  caring for patients, few reports within the rheumatic disease literature have focused on ethical iss
216 basis of the disease has lagged behind other rheumatic diseases mainly because of the difficulty in d
217   Interstitial lung disease is common in the rheumatic diseases, may be caused by a variety of lesion
218 trasound is used in the initial diagnosis of rheumatic diseases, monitoring of the effectiveness of t
219                     They also had thyroid or rheumatic diseases more commonly (42% vs. 13%, P = .006)
220  inherited or acquired, children with severe rheumatic diseases, most notably systemic juvenile idiop
221 ith PBC (n = 30), other autoimmune liver and rheumatic diseases (n = 20), and healthy individuals (n
222   Participants in the National Data Bank for Rheumatic Diseases (NDB) longitudinal study of long-term
223  were enrolled in the National Data Bank for Rheumatic Diseases (NDB).
224 nile idiopathic arthritis (JIA) is a chronic rheumatic disease of childhood.
225 (PMR) is the second most common inflammatory rheumatic disease of the elderly after rheumatoid arthri
226 opens the possibility of clinical testing in rheumatic diseases of childhood.
227 potential to provide novel insights into the rheumatic diseases of childhood.
228 e diagnostics and treatment of patients with rheumatic diseases of the musculoskeletal system, includ
229  the potential to severely affect those with rheumatic diseases or who are taking immunosuppressive t
230 e studied the HAQ-II in 14,038 patients with rheumatic disease over a 2-year period to determine its
231 e risk of developing inflammatory autoimmune rheumatic disease over a lifetime.
232                             As prognosis for rheumatic disease patients continues to improve, the imp
233  inhibitors (statins) to improve outcomes in rheumatic disease patients correlates with the activitie
234         As a result of the chronic nature of rheumatic diseases, pharmacoeconomic evaluations must be
235 tology journals, we identified RCTs of adult rheumatic diseases published in English in 1987-1988 or
236                                Patients with rheumatic diseases receiving certain therapeutic agents
237 mes and other clinical aspects in autoimmune rheumatic diseases reinforce the usefulness of DNA methy
238 isks for rheumatoid arthritis (RA) and other rheumatic diseases remains poor, despite advances in kno
239                                Tracking many rheumatic diseases requires frequent monitoring of patie
240 s available, showcases important advances in rheumatic disease research already powered by these tech
241 t the full potential of their application to rheumatic disease research has yet to be fulfilled.
242     With the growth in patient registries in rheumatic disease research, it is important to validate
243                 A total of 242 patients with rheumatic diseases residing in Massachusetts were recrui
244 y associated with underlying hematologic and rheumatic diseases, respectively.
245 d substantial improvements in the control of rheumatic diseases, resulting in more patients with seve
246 nsive cells in both the bona fide autoimmune rheumatic diseases rheumatoid arthritis and systemic lup
247 se (RR 2.2 [1.6-2.9]), connective tissue and rheumatic diseases (RR 1.5 [1.3-1.7]), peripheral vascul
248 in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL
249                        Children with chronic rheumatic disease should have bone mass monitored by dua
250 tic glucocorticoids have been widely used in rheumatic diseases since they became available over 60 y
251 mic factors at the level of individuals with rheumatic diseases; sometimes, our scope of inquiry expa
252 n the medical interaction with patients with rheumatic disease specifically, there is a large body of
253  concepts in the management of patients with rheumatic diseases specifically, these concepts have bee
254 protein-containing ICs from other autoimmune rheumatic diseases, stimulates plasmacytoid DCs (PDCs) t
255 omplaints, which can present as a definitive rheumatic disease such as calcium pyrophosphate dihydrat
256 st that metals may have a role in triggering rheumatic diseases such as AS and also have implications
257 afety in rheumatoid arthritis (RA) and other rheumatic diseases such as juvenile idiopathic arthritis
258  of sarcoidosis coexisting with or mimicking rheumatic diseases such as systemic lupus erythematosus,
259 n fibrosis is a lethal outcome of autoimmune rheumatic diseases such as systemic sclerosis.
260 nnovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juveni
261  and within inflamed tissue of patients with rheumatic diseases, such as rheumatoid arthritis, system
262 eutrophils in the pathogenesis of autoimmune rheumatic diseases, such as systemic lupus erythematosus
263 A and TST in a large cohort of patients with rheumatic diseases suggest that the IGRA provides greate
264                 Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) hav
265        Similar to the majority of autoimmune rheumatic diseases, systemic sclerosis is characterized
266 irus (CHIKV) infection causes a debilitating rheumatic disease that can persist for months to years,
267 eins, which are autoantigens associated with rheumatic disease that function in RNA biogenesis and qu
268 so called scleroderma, is an immune-mediated rheumatic disease that is characterised by fibrosis of t
269     The spondyloarthropathies are a group of rheumatic diseases that are associated with inflammation
270 related and overlapping chronic inflammatory rheumatic diseases that primarily include ankylosing spo
271  patients with AF with mitral disease and no rheumatic disease, the percentage of fibrosis and the fi
272                                      In many rheumatic diseases, the severity of the condition can re
273                                 As with many rheumatic diseases, there is growing interest in using g
274 er diseases can be extended to patients with rheumatic disease, this review also covers the most sali
275 mediated diseases (diabetes mellitus type 1, rheumatic disease, thyroid disease, vitiligo, alopecia a
276 ppressive agents often require patients with rheumatic diseases to be monitored or managed in the ped
277 ing mysteries in the pathogenesis of several rheumatic diseases, to identify new therapeutic targets
278 icrobiota in patients with IBD, but not with rheumatic disease, toward that of controls.
279           In today's modern day treatment of rheumatic diseases, ultrasonography and magnetic resonan
280  ability to identify and treat children with rheumatic diseases, undermine resident interest in this
281 roup 2 and, within group 1, in patients with rheumatic disease versus nonrheumatic cases.
282 all lifetime risk of inflammatory autoimmune rheumatic disease was 8.4% for women and 5.1% for men.
283 e second most common inflammatory autoimmune rheumatic disease was PMR, with a lifetime risk of 2.4%
284 ra obtained from patients with SLE and other rheumatic diseases was measured by an enzyme-linked immu
285 hat the overall mortality rate for pediatric rheumatic diseases was not increased.
286 using on cancer, cardiovascular disease, and rheumatic diseases, we review longitudinal investigation
287 t four groups of drugs to potentially induce rheumatic diseases were anti-tumour necrosis factor (TNF
288 ystemic lupus erythematosus (SLE), and other rheumatic diseases were identified by diagnostic codes f
289 5 years of age in the National Data Bank for Rheumatic Diseases were used, along with US population d
290                                           In rheumatic diseases, when immune responses are dysregulat
291 onal rehabilitation provided to persons with rheumatic diseases while they are still employed, but at
292       The trial was done in patients without rheumatic disease who tolerated LD-MTX during an active
293 in the treatment of patients with autoimmune rheumatic diseases who have failed conventional therapy.
294 nt IFN pathways active in tissues of complex rheumatic diseases will be critical to classify disease,
295                        Trials treating human rheumatic diseases with biologic agents and drugs that s
296 reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents
297 nt cultural aspects of rehabilitation in the rheumatic diseases with several societal as well as indi
298 es in the biological treatment of autoimmune rheumatic diseases, with a particular focus on systemic
299 ntibody rituximab is a novel therapy for the rheumatic diseases, with an increasing body of evidence
300  is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended firs

 
Page Top